Horizon scanning implanted biosensors in personalising breast cancer management: first pilot study of breast cancer patients views

Ikegwuonu, T., Haddow, G., Tait, J., Murray, A. F. and Kunkler, I. H. (2018) Horizon scanning implanted biosensors in personalising breast cancer management: first pilot study of breast cancer patients views. Health Science Reports, 1(4), e30. (doi: 10.1002/hsr2.30) (PMID:30613798) (PMCID:PMC6266376)

158589.pdf - Published Version
Available under License Creative Commons Attribution.



Aims: This study aimed to explore breast cancer patients' understanding and acceptability of implanted biosensors (BS) within the primary tumour to personalise adjuvant radiotherapy, and to determine optimal design and number of BS, and evaluate potential clinical benefits as well as concerns about tolerance, toxicity, dwell time, and confidentiality of data. Patients and methods: A total of 32 patients treated by surgery (29 breast conserving, 3 mastectomy), postoperative radiotherapy and systemic therapy for early breast cancer, were recruited from a posttreatment radiotherapy clinic at a cancer centre. Patients participated in semistructured interviews. Interview transcripts were analysed using qualitative methods. Results: Participants were aged 39 to 87 years, with a median age of 62 years. Most (N = 23[72%]) were unfamiliar with biosensors. The majority (N = 29[90.6%]) were supportive of the technology's potential use in future breast cancer treatment and were willing to accept biosensors (N = 28[88%]) if they were endorsed by their breast cancer consultant. Only 3 patients expressed concerns, predominantly about uncertainties on their role in the diagnostic and treatment pathway. Patients were flexible about the size and shape of BS, but had a preference for small size (N = 28 [87.5%]). Most (N = 22[69%]) would accept implantation of more than 5 BS and were flexible (N = 22[69%]) about indefinite dwell time. Patients had a strong preference for wireless powering of the BS (N = 28[87.5%]). Few had concerns about loss of confidentiality of data collected. All patients considered biosensors to be potentially of important clinical benefit. Conclusions: While knowledge of biosensors was limited, patients were generally supportive of biosensors implanted within the primary tumour to collect data that might personalise and improve breast cancer radiotherapy in future.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Ikegwuonu, Dr Theresa
Authors: Ikegwuonu, T., Haddow, G., Tait, J., Murray, A. F., and Kunkler, I. H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > MRC/CSO SPHSU
Journal Name:Health Science Reports
ISSN (Online):2398-8835
Published Online:15 March 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Health Science Reports 1(4):e30
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
727671SPHSU Core Renewal: Informing Healthy Public Policy Research ProgrammePeter CraigMedical Research Council (MRC)MC_UU_12017/15IHW - MRC/CSO SPHU